Open Access Open Access  Restricted Access Access granted  Restricted Access Subscription or Fee Access

No 4 (2005)

Articles

Intraoperative urological complications in transurethral surgical interventions on the prostate for benign hyperplasia

Martov A.G., Kornienko S.I., Guschin B.L., Ergakov D.V., Sazonov O.A.

Abstract

Wide clinical introduction of endoscopic methods in management of lower urinary tract (LUT) diseases is explained both by their high efficacy and relative safety. In spite of perfection of endourological tools, no large-scale clinical trials have been performed of late analyzing the rate of complications of endoscopic treatment of benign prostatic hyperplasia (BPH). A total of 5401 transurethral endoscopic operations were made in BPH patients. The spectrum of endoscopic operations made in the Research Institute of Urology (1991-2003) and Krasnodar Regional Hospital N 1 (1998-2003) covered the following operations: transurethral prostatic resection (5003 - 92.6%), transurethral prostatic incision (112 - 2.1%), transurethral rolling electrovaporisation of the prostate (119 - 2.2%), transurethral vaporizing resection of the prostate (107 - 1.98%), transurethral rotoresection of the prostate (60 - 1.1%). Overall number of intraoperative complications was 191 or 3.5%. Most frequent complications were closed and open perforation of the prostatic capsule (1.6 and 0.4%, respectively), a mechanical trauma of the prostate and urethra (0.3 and 0.15%, respectively), development of the syndrome of water intoxication (0.13%), intraoperative blood loss compensated by hemotransfusion (0.5%). Rare complications comprised injury of the ureteral ostia (0.09%), rupture of the urinary bladder (0.02%). Thus, transurethral endoscopic surgery is characterized by high safety, a trend to lowering of the number of intraoperative complications in transurethral endoscopic operations. Adherence to specification and TUR techniques leads to minimization of serious complications number.
Urologiia. 2005;(4):3-8
pages 3-8 views

Optimal treatment of benign prostatic hyperplasia (BPH) with comorbid chronic prostatitis (category III A)

Golubchikov V.A., Sitnikov N.V., Kochetov A.G., Perekhodov S.N., Sidorov O.V., Royuk R.V., Nagornyuk V.N., Tsibizov D.N.

Abstract

The trial of efficacy of physical factors in combined treatment of BPH stage I patients with concomitant abacterial chronic prostatitis (category IIIA) enrolled 42 patients who were divided into two groups. Group 1 received combined treatment including complex physical factors (CAP-ELM-01). The efficacy of the treatment was judged by dynamics of clinical and device indices and severity of leading CP syndromes. It is shown that physical factors contributed to noticeable improvement in the parameters of prostatic secretion, uroflowmetry, size of the prostate, hemodynamics, clinical manifestations of chronic prostatitis.
Urologiia. 2005;(4):9-12
pages 9-12 views

Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma

Likhin F.A., Bartnovsky A.E., Vdovichenko K.K., Abramov A.A., Belokhvostov A.S.

Abstract

The study was made of possibilities of methyl-specific PCR-test of glutathione-S-transferase PI (GSTP1) gene in differential diagnosis of prostatic cancer: sensitivity of the test, comparison of reagents of Russian and foreign production. Blood plasm and cellur urinary precipitate DNA was investigated in patients with prostatic adenocarcinoma. The results show that the above test with domestic reagents is rather perspective for differential diagnosis.
Urologiia. 2005;(4):12-15
pages 12-15 views

Prognostic implications of GP3a glucoprotein gene PLA1/PLA2 allele in prostatic cancer: pilot results of the study

Loran O.B., Itkes A.V., Seregin A.A., Myandina G.I.

Abstract

We studied the role of integrins, primarily, the role of allele distribution of GP3a gene in development of prostatic cancer (PC) and assessment of its prognostic significance. From November 2003 to May 2004 we examined 32 patients with PC: 11 patients with local PC T1-2N0M0; 14 patients with locally advanced cancer T3N0M0 and 7 patients with invasive and/or metastatic cancer T3-4N1M0-1 or T3-4N0-1M1. The blood from all the patients we studied with PCR for alleles of GP3a gene, PSA. Seventeen patients were found to have alleles PLAIAI, 14(44%) - alleles PLA1A2, 1(3%) - alleles PLA2A2. Alleles PLA1A2 occurred significantly more often than in the population (p < 0.005). The group analysis has found that 8 patients with local PC had alleles PLAIAI, 3 patients - alleles PLA1A2 (27%). We discovered alleles PLA2A2, PLAIAI and PLA1A2 in 1(7%), 5(36%) and 8(57%) patients with locally advanced PC, respectively. Among patients with metastatic and/or invasive prostatic cancer, there were 4 (57%) and 3 (43%) cases of alleles PLAIAI and PLA1A2, respectively. Our study demonstrated influence of carriage of PLA2 allele on occurrence of PC risk (5-fold higher) and its invasive forms (10-fold higher and more). Probability to develop local invasion among patients with prostatic cancer - carriers allele PLA1A2 is 6 times higher than among carriers of alleles PLAIAI. A PC course in carriers of alleles PLA1A2 may be characterized by faster development of local invasion and metastasizing vs carriers of alleles PLAIAI. These findings can be used in design of nomograms for prognostication of invasion of clinically small tumors in verification of significance on greater number of the patients.
Urologiia. 2005;(4):16-19
pages 16-19 views

Chemotherapy of hormone-resistent cancer of the prostate

Matveev B.P., Bukharkin B.V., Kalinin S.A.

Abstract

A total of 59 patients with hormone-resistent prostatic cancer (HDPC) treated in 1999-2004 entered the trial. Three schemes of first-line chemotherapy were examined for clinical efficacy and toxicity in the above patients. Anticancer combined treatment vinorelbin + cycloplatam was given to 23 patients, mitoxantron + prednisolone - to 23 patients, mitoxantron+cysplatin+prednisolone - to 13 patients. The latter scheme was most effect and toxic. Partial regression of metastases and a 50% decrease in the initial PCA level were seen in 23% cases. Vinorelbin+cycloplatam was less effective and toxic: partial regression of metastases - 13%, PSA regression - 17.4%. The least efficacy and toxicity were observed in the treatment with mitoxantron+prednisolone - 8.7%. Thus, the above first-line HDPC therapy was most effective but has the highest toxicity in using the scheme mitoxantron+cysplatin+prednisolone.
Urologiia. 2005;(4):20-23
pages 20-23 views

Hormonal, radiation and combined therapy of locally advanced prostatic cancer (T3NXM0)

Pavlov A.S., Loran O.B., Simakina E.P., Tomkevich B.A., Repina A.G., Gribova R.G.

Abstract

The analysis is presented of combined treatment of locally advanced prostatic cancer (LAPC), stage T3NXM0, in 158 LAPC patients treated in 1998-2002. The patients were divided into four groups: group 1 (n = 72) received hormones in parallel with radiation, group 2 (n = 52) received only hormones, group 3 (n = 27) received radiotherapy after failure of long-term (1 year and more) hormone therapy, group 4 (n = 7) was given teleradiotherapy only. 3-year recurrencefree survival in patients with LAPC showed advantage of the combined treatment (82 + 0.1%) vs hormone (56 ±0.1%) or radiation (69.3 + ± 0.1%) therapy alone. It provides a high local control over the primary tumor and an increase of survival, prolongs distant metastases free period, improves the patients' quality of life and their adaptation.
Urologiia. 2005;(4):24-26
pages 24-26 views

Quality of life in patients after radical prostatectomy

Kamalov A.A., Khomeriki G.G., Efremov E.A., Romikh V.V., Egorov A.A., Okhobotov D.A.

Abstract

According to the literature, after radical prostatectomy the patients had normal micturition and erectile function in 50 and 10-30%, respectively. A total of 647 patients with diagnosis prostatic cancer (PC) stage Tla-T4 were examined in two clinics in 1997-2003. Of them, 43 patients (PC stage Tla-ТЗа) have undergone retropubic radical prostatectomy (RRP) by a modified nerve-preserving technique (preservation of the urinary bladder neck, puboprostatic joints in prostate size > 60 cm). Preoperative and postoperative examinations for urine continence and erectile function after RRP were made in 20 patients. The proposed operative technique of nerve-preserving RRP preserves urine continence and erectile function in many cases. This improves social adaptation of the patients and extends indications for operative treatment.
Urologiia. 2005;(4):27-29
pages 27-29 views

A phytogenic drug kanefron® H in patients with chronic cystitis and urolithiasis

Alyaev Y.G., Amosov A.V., Grigoryan V.A., Sultanova E.A., Krupinov G.E., Akopyan G.N.

Abstract

To evaluate efficacy of kanefron Hs (KH) in combined therapy of chronic cystitis and urolithiasis (after extracorporeal shock-wave lithotripsy-ESWL), we examined 48 women suffering from chronic cystitis. The patients were divided into two groups by the presence of pyuria: 20 patients of group 1 had pyuria, 28 patients of group 2 had no pyuria. Each group was subdivided into two groups in relation to KH. Subgroup la received phosphomycin as monotherapy, subgroup lb - phosphomycin with KH (2 pellets 3 times a day for 30 days). Subgroup 2a was initially treated with anti-inflammatory drugs, local medication physiotherapy, circulation improving drugs for 10 days. Then the patients were followed up for a months without any treatment. Subgroup 2b received the same initial course but it was followed for 30 days with KH. 79 patients with urolithiasis (uroliths and ureteroliths) have undergone ESWL. 45 entered KH group (2 pellets 3 times a day), 34 - the control group (spasmolytic and anti-inflammatory therapy). KH in combined treatment of chronic cystitis raises efficacy of the initial therapy (antibacterial or combined, made in the absence of pyuria), promotes achievement of longer disease remission, elimination of concrement fragments from the urinary tract. Long-term administration of KH induce no side effects. Thus, KH can be recommended in chronic cystitis and urolithiasis in patients exposed to ESWL as an effective and safe drug.
Urologiia. 2005;(4):29-33
pages 29-33 views

Results of surgical treatment of coral nephrolithiasis

Kamynina S.A., Yanenko E.K., Obukhova T.V.

Abstract

A total of 98 patients (39 males and 59 females) with coral nephrolithiasis (CN) were divided into 3 groups depending on the variant of surgical treatment. The results were followed up for 5 years. Group 1 and 2 patients have undergone combined low-traumatic open surgery or low-invasive interventions (extracorporeal lithotripsy - ECL or percutaneous nephrometolapaxy - PN), group 3 patients - open surgery (pyelonephrolithotomy or section nephrolithotomy. It was found that the treatment was longest in group 1 and shortest in group 3, complications occurred most frequently in group 3 on section nephrolithotomy, least frequently in group 2. A significant decline of operated on kidney late after the treatment was observed in patients subjected to section nephrolithotomy. Thus, ECL and PN produce positive results in patients with CN (elimination of the stone with a minimal risk of residual concrements) in good long-term function of the operated on kidney.
Urologiia. 2005;(4):33-36
pages 33-36 views

Tamsulosin in the treatment of patients with ureteroliths of the lower third of the ureter clinical and pharmacoeconomic grounds

Avdoshin V.P., Andryukhin M.I., Barabash M.I., Taskinen Y.l., Olshanskaya E.V., Motin P.I., Khaidar M.

Abstract

Alphal-adrenoblocker tamsulosin reduces muscle spasm in the ureteric wall, decreases peristalsis below and raises pressure above the stone thus facilitating stone passage. Patients on tamsulosin had spontaneous stone passage in 73.8% cases while only 22.4% patients on routine therapy became stone free. Tamsulosin also shortens hospital stay. Use of tamsulosin 0.4 mg daily in patients with distal ureteric stones is pathogenetically validated, is highly clinically and cost effective.
Urologiia. 2005;(4):36-39
pages 36-39 views

Clinical features and urolithiasis risk factors in urinary tuberculosis

Petrunin Y.A., Nersesyan Y.A., Yuryeva A.A., Alekseeva N.V.
Urologiia. 2005;(4):39-42
pages 39-42 views

Use of cryoprecipitate in combined therapy of acute purulent pyelonephritis

Neimark A.I., Gatkin M.Y.

Abstract

The treatment of 120 patients with acute purulent pyelonephritis (APP) brought about the following results. 86% patients given standard therapy showed deterioration of their condition, D1C syndrome and inflammatory process were not cured, pyoinflammatory process in the kidney continued. On the contrary, 84.1% patients on combined conservative treatment improved: D1C syndrome and active inflammation relieved, fibronectin content, IgA, IgM and IgG levels rose. Ultrasonic examination and dopplerography indicated that combined conservative therapy including cryoprecipitate arrested development of a purulent focus in the kidney, reestablished intraorganic circulation. Mean stay in hospital was 13.9 days.
Urologiia. 2005;(4):42-48
pages 42-48 views

Efficacy of probiotic bactisporin in therapy of intrahospital urinary infection

Pushkarev A.M.

Abstract

We studied efficacy of bactisporin (probiotic based on aerobic spore-forming culture Bacillus subtilis, strain 3H) in combined treatment of intrahospital urinary infection (IUI) in 36 patients with intravesical obstruction. These patients developed postoperative complications due to IUI caused by antibiotic-resistant hospital flora. The control group consisted of 35 patients matched by age and disease given conventional postoperative etiotropic therapy. Bacterial translocation enables bactisporin to enter blood through gastric mucosa. Blood flow delivered the drug to the inflammation focus. Bactisporin can also directly affect IUI pathogen if bacterial suspension is introduced into the cavity. Bacteriological efficacy of the etiotropic scheme including bactisporin against Proteus spp., Ps aeruginosa, Enterobaeter spp., Klebsiella spp. made up 72.7-92%. Bactisporin shortened the time of clinical normalization as well as normalization of absolute count of T - and B-lymphocytes, phagocyting leukocytes and immunoglobulin G. Thus, probiotic bactisporin is effective against antibiotic-resistant agents of IUI. It also stimulates immunity promoting clinieoimmunological remission.
Urologiia. 2005;(4):48-53
pages 48-53 views

A retrospective analysis of morphological tests in patients with interstitial cystitis

Pushkar D.Y., Zaitsev A.M., Gundorova L.V., Kovylina M.V.

Abstract

Cystoscopy, hydrobougieurage and biopsy of the urinary bladder were made in 80 female patients with interstitial cystitis (1С) aged 2368 years. Endoscopic changes were estimated by an original scale. The analysis of the endoscopic findings revealed a correlation between duration of the process, cystoscopic picture and histopathological evidence. Clinical and cystoscopic pictures provide significant information on morphological changes in the wall of the urinary bladder depending on the disease stage. Histological study of urinary bladder biopsies in 1С is used rather forexcluding other diseases of the urinary bladder with similar clinical symptoms (primarily cancer and tuberculosis).
Urologiia. 2005;(4):53-56
pages 53-56 views

Trospium chloride in the treatment of idiopathic and neurogenic detrusor overactivity

Mazo E.B., Krivoborodov G.G., Shkolnikov M.E., Babanina G.A., Kozyrev S.V., Korshunova E.S.

Abstract

The aim of the study was to investigate safety and efficacy of spasmex (trospium chloride) in patients with idiopathic and neurogenic detrusor overactivity. The study included 66 patients with idiopathic and neurogenic detrusor overactivity. The diagnostic scheme consisted of voiding dairy for 72 hours, laboratory tests, ultrasound investigation with measurement of residual urine volume, urodynamic investigation and neurologic examination. The patients were divided into 4 groups- 15 patients with idiopathic detrusor overactivity (DOA), 16 with neurogenic DOA, 23 with combination of DOA with benign prostatic hyperplasia, 12 with overactive bladder without DOA. Initial trospium chloride dose of 15 mg/day (5 mg 3 times a day) followed by dose titration to obtain clinical efficacy was used under residual urine volume control every week. The maximal dose was 45 mg. After 12 weeks reduction of micturation frequency was registered in all the groups Administration of small dose trospium chloride (15 mg) resulted in subjective improvement in 63 (94.5%) patients. Only 3 patients persisted with the symptoms in whom the dose was raised to 30 mg and then to 45 mg/day. Thus, spasmex demonstrated high efficacy in patients with bladder overactivity. High efficacy and safety with low cost make spasmex a drug of choice in the majority of patients with overactive bladder symptoms.
Urologiia. 2005;(4):56-59
pages 56-59 views

Sildenafil citrate in diagnosis of erectile dysfunction

Tarasov N.I., Bavilsky V.F., Plaksin O.F., Matygin A.S.

Abstract

We examined 86 patients: 24 with functional and 62 with organic erectile dysfunction (EDF). In functional EDF, sildenafil citrate (SC) in a dose 25-50 mg or intracavernous injection of 2% solution of papaverin always resulted in satisfactory erection. In EDF, SC, papaverin injection and LOD test results were compared. Morphological examinations of cavernous tissue and tunical albuginea of the penis. Correlations were found between clinical findings, results of SC and intracavernous papaverin solution administration, LOD-test, morphological evidence. This provides objective data for classification of EDF into three stages (I, II and III). Stages I and II were defined as compensated, stage III - as a decompensated stage of organic erectile dysfunction. SC has some advantages over other tests, therefore it is recommended as a monomethod for diagnosis of functional forms, indirect staging of organic EDF.
Urologiia. 2005;(4):59-64
pages 59-64 views

Postcompression test in diagnosis of vasculogenic erectile dysfunction

Mazo E.B., Gomidov S.I., Ovchinnikov R.I., Andranovich S.V., Iremashvili V.V.
Urologiia. 2005;(4):64-69
pages 64-69 views

Prenatal differential diagnosis of fetal urinary malformations

Chekhonatskaya M.L., Glybochko P.V., Demidov V.N.

Abstract

To elaborate prenatal differential-diagnostic criteria of functional and obstructive uropathies, we examined 3287 pregnant women. Obstructive fetal urinary malformations (FUM) were detected in 42 (1.3%) cases. Prenatal ultrasonic assessment of fetal pelvis size depending on filling of the urinary bladder allowed identification of two groups: bladder-independent and bladder-dependent. Basing on our findings, we established prognostically significant differential-diagnostic criteria of a FUM variant. Thus, dependence of the size of caliculopelvic complex and the ureter on filling of the urinary bladder is a basic echographic criterion in functional obstruction. The absence of such dependence is the criterion of organic obstruction.
Urologiia. 2005;(4):69-72
pages 69-72 views

Obstructive uropathy

Khvorostov I.N., Zorkin S.N., Smirnov I.E.
Urologiia. 2005;(4):73-76
pages 73-76 views
pages 77-77 views
pages 78-78 views

Yury Mikhailovich Zakhmatov

- -.
Urologiia. 2005;(4):79-79
pages 79-79 views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies